Trevena (NASDAQ: TRVN): A Biotech Low Float Runner
Trevena (NASDAQ: TRVN) announced that its partner, Jiangsu Nhwa, has received approval from China's National Medical Products Administration (NMPA) for its opioid pain medication, Olinvyk.
Stay updated with breaking news from Trvn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Trevena (NASDAQ: TRVN) announced that its partner, Jiangsu Nhwa, has received approval from China's National Medical Products Administration (NMPA) for its opioid pain medication, Olinvyk.
Trevena, Inc. (NASDAQ:TRVN – Get Rating) was the target of some unusual options trading activity on Monday. Stock investors bought 2,717 call options on the company. This is an increase of approximately 7,891% compared to the average volume of 34 call options. Trevena Stock Up 277.8 % Trevena stock traded up $1.75 during midday trading […]
Trevena, Inc. (NASDAQ:TRVN – Get Rating) was the target of some unusual options trading activity on Monday. Stock investors bought 2,717 call options on the company. This is an increase of approximately 7,891% compared to the average volume of 34 call options. Institutional Inflows and Outflows A number of hedge funds and other institutional investors […]
StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a research report sent to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other research analysts have also recently commented on TRVN. JMP Securities reaffirmed a market outperform rating and issued a $2.00 target […]
Equities researchers at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on TRVN. HC Wainwright dropped their price target on Trevena from […]